Furby, Hannah http://orcid.org/0000-0002-7279-1812
Moore, Suzanne
Nordstroem, Anna-Lena
Houghton, Richard
Lambrelli, Dimitra
Graham, Sophie
Svenningsson, Per
Petersén, Åsa
Funding for this research was provided by:
F. Hoffmann-La Roche
Article History
Received: 17 June 2022
Revised: 30 September 2022
Accepted: 2 October 2022
First Online: 18 October 2022
Declarations
:
: AP is funded by research grants from the Swedish Research Council (grant number 2018/02559), the National Health Services in Sweden as well as the Knut and Alice Wallenberg Foundation as Wallenberg Clinical Scholar (# 2019.0467). DL and SG are salaried employees of Evidera, the consultancy company hired by F. Hoffmann-La Roche Ltd. to perform this work. HF, ALN, SM & RH are all employees of Roche, which has a drugs for Huntington’s Disease under clinical development. HF, SM, ALN and RH are shareholders in F. Hoffmann‐La Roche Ltd. PS declares no conflicts of interest.
: Ethical approval was obtained from the Swedish Ethical review board (Etikprövningsmyndigheten; approval number 2020-07037). The Swedish National Board for Health and Welfare (Socialstyrelsen) also conducted a privacy assessment prior to data release.